Rite Aid Corporation

OTCPK:RADC.Q Lagerbericht

Marktkapitalisierung: US$2.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Rite Aid Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Jeffrey Stein

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements2.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5.4yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • Oct 16

Rite Aid Shareholders Are Wiped Out Under A Chapter 11 Bankruptcy Plan

Summary Rite Aid File for Ch.11 bankruptcy on October 15. Under the plan shareholders get no recovery and shares will be cancelled. There is a stalking horse bid of $575 million for Elixir. Secured noteholders get 100% of the new equity. McKesson is trying to terminate their supply contract with Rite Aid. Read the full article on Seeking Alpha
Seeking Alpha • Jul 10

Rite Aid May Be Forced Into Ch.11 Bankruptcy To Resolve Opioid Liabilities

Summary Rite Aid's stock is being downgraded from "Hold" to "Sell" due to the opioid lawsuit, ongoing financial losses, and ineffective management. Rite Aid reported a $(5.56) net loss per share for 1Q. Elixir will discontinue their Medicare Part D program for individuals starting next year. The stock is effectively trading at only about $0.08 after adjusting for the 1-20 reverse stock split a few years ago. Read the full article on Seeking Alpha
Seeking Alpha • Jun 27

Rite Aid Q1 Earnings Preview: Bears Remain In Control

Summary Bears remain resolute in their strong bet against Rite Aid. Weak outlook from Walgreens hurt RAD stock ahead of the Q1 2024 report. Debt leverage and cost run rate remain a concern. Read the full article on Seeking Alpha
Seeking Alpha • Jan 09

Rite Aid names interim CEO as Heyward Donigan departs

Healthcare industry expert Elizabeth Burr has been elected as interim CEO at U.S. drugstore chain Rite Aid (NYSE:RAD), effective immediately. Burr, a member of the company’s board, will succeed president and CEO Heyward Donigan, who has left the company. She has extensive experience in the health industry, having previously served as VP, Head of Health Ventures and Chief Innovation Officer at Humana. The firm has initiated a search to identify a permanent CEO and has retained a leading executive search firm. In addition, Rite Aid (RAD) reiterated its fiscal 2023 financial guidance for total revenues of $23.7B and $24B vs. $21.63B consensus, net loss between $584M and $551M, adjusted EBITDA between $410M and $440M and capital expenditures of ~$225M. RAD shares gained 2% in Monday's premarket session
Seeking Alpha • Dec 20

Rite Aid Q3 2023 Earnings Preview

Rite Aid (NYSE:RAD) is scheduled to announce Q3 earnings results on Wednesday, December 21st, before market open. The consensus EPS Estimate is -$0.31 and the consensus Revenue Estimate is $5.94B (-4.7% Y/Y). Over the last 2 years, RAD has beaten EPS estimates 75% of the time and has beaten revenue estimates 63% of the time. Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.
Seeking Alpha • Nov 15

Rite Aid spikes 20% on above average volume

The beaten-down pharmacy retailer Rite Aid Corporation (NYSE:RAD) climbed ~20% Tuesday on above-average volume, rallying alongside a buoyant broader market. About 3.0M Rite Aid (RAD) shares have changed hands compared to the 65-day average volume of ~2.6M. However, with its stock continuing to trade ~48% below the year-ago level, Rite Aid (RAD) shares have yet to surpass the mid-September levels. About 18% of the company’s float represents short interest. The rally coincides with gains in the major indices after Walmart (WMT) topped Street forecasts with its Q3 2022 results, and data on producer prices indicated signs of moderating inflation. Wall Street has remained bearish on Rite Aid (RAD) stock, with an average rating of Strong Sell from analysts. However, the Seeking Alpha Author ratings identify RAD as a Hold alongside SA’s Quant System, which consistently beats the market.
Seeking Alpha • Oct 11

Rite Aid partners with Google Cloud on pharmacy insights, customer engagement

Rite Aid (NYSE:RAD) has brokered a partnership with Google Cloud (NASDAQ:GOOG) that will provide the drug store chain with improved insights and customer experiences, as well as access to the Anthos platform for application deployment. Anthos will provide Rite Aid's (RAD) pharmacies with cloud computing capabilities on-site. In addition, it will support a vaccine scheduling tool, customer messaging infrastructure, and digital engagement platform. Rite Aid (RAD) will also benefit from Google Cloud's (GOOG) Retail Search product that provides customers with precise search results when shopping on the company's website. Also, Rite Aid (RAD) will migrate its enterprise data to Google Cloud (GOOG) using BigQuery which will provide improved insights into its finances, supply chain inventory, and customer information, powering data-driven decisions for its business operations. Check out why Seeking Alpha contributor WYCO Researcher rates Rite Aid (RAD) a hold.

Geschäftsführer

Jeffrey Stein (55 yo)

less than a year
Amtszeit

Mr. Jeffrey Scott Stein is Chief Executive Officer and Chief Restructuring Officer at Rite Aid Corporation since October 16, 2023 and its Director since August 2024. He serves as Chief restructuring office...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Matthew Schroeder
CFO & Executive VP5.5yrsUS$2.75m0.36%
$ 7.8k
Jeffrey Stein
CEO, Chief Restructuring Officer & Directorless than a yearkeine Datenkeine Daten
Steven Bixler
Chief Accounting Officer & Senior VP1.7yrskeine Daten0.0065%
$ 141.5
Byron Purcell
Vice President of Investor Relations & Treasurerno datakeine Datenkeine Daten
Christin Bassett
Acting General Counsel & Corporate Secretaryless than a yearkeine Datenkeine Daten
Joy Seusing
Senior VP & Chief Communications Officerno datakeine Datenkeine Daten
Jeanniey Walden
Senior VP & CMO1.5yrskeine Datenkeine Daten
Jessica Kazmaier
Executive VP5.5yrskeine Daten0.16%
$ 3.6k
Karen Staniforth
Senior VP of Clinical Pharmacy Services & Chief Pharmacy Officer2.5yrskeine Datenkeine Daten
Angele Robinson-Gaylord
Senior Vice President of Store Development3.9yrskeine Datenkeine Daten
Christopher DuPaul
Executive Vice President2.7yrskeine Daten0.063%
$ 1.4k
2.5yrs
Durchschnittliche Betriebszugehörigkeit
54yo
Durchschnittliches Alter

Erfahrenes Management: RADC.QDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Jeffrey Stein
CEO, Chief Restructuring Officer & Directorless than a yearkeine Datenkeine Daten
Robert Knowling
Independent Director5.9yrsUS$264.55k0%
$ 0
Arun Nayar
Independent Director5.9yrsUS$270.00k0.000050%
$ 1.1
Bruce Bodaken
Independent Chairman of the Board11.3yrsUS$425.00k0.012%
$ 258.6
Elizabeth Burr
Director5.4yrsUS$858.46k0%
$ 0
Carrie Teffner
Directorless than a yearkeine Datenkeine Daten
Paul Keglevic
Directorless than a yearkeine Datenkeine Daten
Bari Harlam
Independent Director4yrsUS$272.63k0%
$ 0
Katherine Quinn
Independent Director5.4yrsUS$283.75k0%
$ 0
5.4yrs
Durchschnittliche Betriebszugehörigkeit
62yo
Durchschnittliches Alter

Erfahrener Vorstand: RADC.QDie Vorstandsmitglieder gelten als erfahren (5.4 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2024/09/03 13:41
Aktienkurs zum Tagesende2024/09/03 00:00
Gewinne2023/09/02
Jährliche Einnahmen2023/03/04

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Rite Aid Corporation wird von 16 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Steven ValiquetteBofA Global Research
William FrohnhoeferBTIG
George HillDeutsche Bank